Blue Horizon International and Mehling Orthopedics to exhibit at American Academy Of Orthopaedic Surgeons Annual Meeting in Chicago

Brian Mehling, M.D. and Pavel Yufit, M.D., orthopedic surgeons with practices in New York and New Jersey, are scheduled to attend the 2022 Annual Meeting of the American Academy of Orthopaedic Surgeons in Chicago, Illinois from March 22-26, 2022 at the McCormick Place Convention Center. The booth number is 1904.

This is the world’s largest meeting of orthopaedic surgeons, researchers, and allied health professionals. The meeting offers physicians the opportunity to exchange ideas with their colleagues and learn about cutting-edge technology in their field.

Dr. Mehling is also the chief medical officer at BHI Therapeutic Sciences, LLC, a company that offers a novel method of arthritis therapy using a patient’s own stromal vascular fraction (SVF) cells including mesenchymal stem cells and Wharton’s Jelly mesenchymal stem cells. 

BHI Therapeutic Sciences and Blue Horizon International (BHI) will exhibit at the conference to introduce data outcomes from its program located at Malacky Hospital in Slovakia. 

“Stem cell therapy is primarily intended for patients with a diagnosis of joint osteoarthritis, whether being a gonarthrosis or coxarthrosis of first and second degree. Malacky Hospital is the only medical institute performing treatment of hip and knee osteoarthrosis with stem cells using the technology of BHI,” said Dr. Mehling.

Doreen Santora, CEO of BHI and BHI Therapeutic Sciences, LLC, who will be also attending the AAOS meeting added, “Malacky Hospital is a private hospital located in the western part of Slovakia, just a short car ride from Vienna. It offers high-quality, comprehensive, and customized healthcare solutions to organizations and individuals and it is staffed with expertly-trained medical professionals and is one of the premiere hospitals in Central Europe.”

Mehling Orthopedics performs complex orthopedic fracture surgeries, including high velocity fractures, open fractures and complex pelvic ring injuries as well as general orthopedic and sports medicine surgeries.  Their team of experts delivers specialized care for orthopedic traumatic injuries. With all doctors certified by the American Board of Orthopedic Surgeons, they are committed to providing the finest medical care possible. For more information, please visit www.mehlingorthopedics.com.

BHI Therapeutic Sciences, LLC is currently offering cord blood, Wharton’s Jelly mesenchymal stem cells, bone marrow and adipose stem cell derived treatments at Malacky Hospital in Slovakia and in Jamaica. More information, please visit www.bhisciences.com.


The American Academy of Orthopaedic Surgeons (AAOS) provides education and practice management services for orthopaedic surgeons and allied health professionals. The Academy serves as an advocate for improved patient care and informs the public about the science of orthopaedics and it serves more than 39,000 members worldwide. For more information, please visit www.aaos.org.

Brian Mehling, MD slated to participate in the 19th Annual World Congress of Society for Brain Mapping and Therapeutics

Breaking Boundaries of Science, Technology, Medicine, Art, and Healthcare Policy meeting being held in LA March 10-13

Brian Mehling, MD, founder and chief medical officer of BHI Therapeutic Sciences, will virtually present on three topics at the 19th Annual World Congress of Society for Brain Mapping and Therapeutics. The meeting, entitled Breaking Boundaries of Science, Technology, Medicine, Art, and Healthcare Policy, will be held at the Los Angeles Convention Center, March 10-13.


Dr. Mehling will speak on the following: Safety study of Cultured Wharton’s Jelly Mesenchymal Stem Cells, Umbilical cord-derived stem cell therapy for multiple sclerosis treatment – a single subject case study, and Mesenchymal stem cell therapy for drowning induced hypoxic brain injury – A pediatric case report study of recovery.

Dr. Mehling is a board-certified American orthopedic trauma surgeon, researcher, and philanthropist. He is spearheading groundbreaking research in stem cell therapy focused on treatment and research using stem cells. He is also board-certified in anti-aging and regenerative medicine.
“We are focused on bringing advanced stem cell therapies within reach of a wider audience, “said Dr. Mehling. We envision a future in which stem cells are preferred over many surgical, pharmacological, and rehabilitative medical services,” he added. He and his colleagues are conducting clinical investigations to evaluate the safety and efficacy of adult stem cells in therapy of chronic inflammation, musculoskeletal conditions, stroke, spinal cord injury and other medical conditions.


This program is jointly Sponsored by Johns Hopkins University School of Medicine and Saint Louis University School of Medicine for Continuing Medical Education (CME) including 700+ presentations (live and virtual),13 keynotes, three panel discussions, and two bio-skills labs (Brain and Spine).

BHI Therapeutic Sciences (BHITS) is pioneering ethical, effective, safe and affordable stem cell treatment therapies utilizing cord blood stem cells (those that are harvesting from an umbilical cord in the case of a C-Section, bringing no injury or risk to mother or baby).
Stem cells are a special kind of cell that can be used to regenerate the human body
without drugs or surgery, treating the leading diseases and injuries shortening our life spans and causing millions of people to live in chronic pain.


Media Contact
Doreen Santora 201-342-7662
dsantora@bluehorizoninternational.com

BHI CEO Participates in Patient Safety Workshop Sponsored by the Joint Commission

Doreen Santora, RN, MHA

Doreen Santora, RN, MHA, chief executive officer of Blue Horizon International (BHI) and its subsidiaries, including BHI Therapeutic Sciences, recently participated the Joint Commission International (JCI) program titled Managing Patient Safety Events: A Root Cause Analysis Workshop.


The two-day, live virtual workshop provided participants with the knowledge, skills, and strategies to establish a standardized approach to managing patient safety events, including sentinel events.


“BHI Therapeutic Sciences is committed to providing the highest quality and safest care,” said Brian Mehling, MD, founder and chief medical officer of BHI. “I applaud our leadership and our team for always seeking new information and education in order to provide better clinical outcomes and experiences for our patients,” he said.
Doreen Santora has more than 30 years of healthcare management experience. A registered nurse with a Master of Science degree in health administration, she serves as the Chief Executive Officer of Blue Horizon International (BHI) and all its subsidiaries. Most recently, Ms. Santora was recognized as a top nurse by the International Nurses Association and is featured in the publication Worldwide Leaders in Healthcare. She received this honor for her outstanding achievements, commitment to education, and demonstrated leadership in her field.


BHI specializes in bringing quality stem cell, regenerative, and related biologic technologies and therapies to emerging and established markets in a safe and ethical manner. She is responsible for the oversight of the day-to-day operations of BHI and places a strong emphasis on quality assurance and patient satisfaction.


Under her leadership, BHI has opened two successful stem cell therapy clinics in Jamaica and Slovakia.
Ms. Santora focuses on providing outstanding medical care in a high quality, patient friendly environment. Prior to her position here, she served as senior vice president of operations at one of the busiest and most respected healthcare institutions in the United States, Hackensack University Medical Center. She was responsible for the growth and development of several nationally and internationally clinical programs that received numerous healthcare awards and distinctions.


The Joint Commission is the recognized global leader for healthcare accreditation. JCI is the author of rigorous international standards on quality and patient safety. These standards serve as the foundation of an evaluation process that helps healthcare organizations measure, assess, and continuously improve performance.